QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company is headquartered in Venlo, Limburg and currently employs 5,654 full-time employees. The firm is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The firm's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
Mr. Thierry Bernard est le Chief Executive Officer de Qiagen NV, il a rejoint l'entreprise depuis 2020.
Quelle est la performance du prix de l'action QGEN ?
Le prix actuel de QGEN est de $39.49, il a diminué de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Qiagen NV ?
Qiagen NV appartient à l'industrie Life Sciences Tools & Services et le secteur est Health Care
Quel est la capitalisation boursière de Qiagen NV ?
La capitalisation boursière actuelle de Qiagen NV est de $8.1B
Est-ce que Qiagen NV est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 18 analystes ont établi des notations d'analystes pour Qiagen NV, y compris 5 achat fort, 8 achat, 11 maintien, 0 vente et 5 vente forte